Diffuse large B-cell lymphomas with aberrations in MYC, BCL2 and/or BCL6 by genetic
alterations or protein expression represent a group of high grade B-cell lymphomas with …

Double-hit lymphoma (DHL) is a subgroup of aggressive lymphomas with both MYC and
BCL2 gene rearrangements, characterised by a rapidly progressing clinical course that is …

Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-
cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by …

The 2016 revision of the World Health Organization (WHO) classification for lymphoma has
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …

Personalized therapy for the treatment of patients with cancer is rapidly approaching and is
an achievable goal in the near future. A substantial number of novel targets have been …

The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of
cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide …

Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of
distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and …

Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological
subtypes, resulting in a broad range of clinical outcomes. With standard …

The emerging molecular and prognostic characterization of diffuse large B-cell lymphoma
(DLBCL) has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and …

Improved delineation of lymphoid malignancy biology has prompted refinement of the 2008
World Health Organization (WHO) classification of hematopoietic and lymphoid tumors with …